Abstract:Background: Transforming growth factor-beta (TGF-β), an immunosuppressive cytokine, is often elevated in various tumors and inhibits the immune system's ability to combat tumor cells. Despite promising results from TGF-β inhibitor therapies, their clinical efficacy remains limited. Purpose: This study aimed to enhance the antitumor capabilities of natural killer (NK) cells in the presence of TGF-β by exploring the potential of asiaticoside, a natural compound with established clinical safety. Study design: The effects of asiaticoside on NK cells were investigated to determine its potential to counteract TGF-β-induced immunosuppression and elucidate the underlying mechanisms. Methods: Natural compounds were screened using a Luminex assay to identify those promoting Interferon-γ (IFN-γ) secretion from NK cells. Asiaticoside-pretreated NK cells' cytotoxicity was assessed against K562, OVCAR8, and A2780 cells using organoids from ascites-derived ovarian cancer (OC) cells. In vivo efficacy was evaluated with B16 melanoma lung metastasis and subcutaneous tumor models in C57BL/6 mice, using asiaticoside as a 50 mg/kg injection. The compound's ability to enhance NK cell-driven anti-neoplastic responses was further assessed in an OC murine model. Effects on TGF-β/SMAD pathways and mitochondrial functions were examined through various microscopy and metabolomic techniques. The involvement of the mTOR/DRP1 axis in asiaticoside-mediated restoration of mitochondrial oxidation in NK cells after TGF-β suppression was determined using the mTOR inhibitor rapamycin and the DRP1 inhibitor Mdivi-1. Results: Asiaticoside-treated NK cells retained their ability to suppress tumor growth and metastasis despite TGF-β presence. Asiaticoside downregulated TGF-β receptors 1 (TGFBR1) expression, impaired the protein stability of TGFBR1 and TGF-β receptors 2 (TGFBR2), and reduced SMAD2 phosphorylation, preventing SMAD2 translocation from the mitochondria. This preserved mitochondrial respiration and maintained NK cell antitumor activity. Conclusion: The study concludes that asiaticoside has significant potential as a strategy for "priming" NK cells in cellular immunotherapy. By demonstrating that asiaticoside degrades the TGF-β receptor, leading to reduced phosphorylation of SMAD2 and preventing its mitochondrial translocation, thereby maintaining mitochondrial integrity. Meantime, asiaticoside counteracts TGF-β-induced suppression of mitochondrial oxidative and aerobic respiration through the mTOR/DRP1 pathways. The research uncovers a previously unreported pathway for preserving mitochondrial respiration and NK cell functionality. A detailed mechanistic insight into how asiaticoside functions at the molecular level was explored. Its ability to counteract the immunosuppressive effects of TGF-β makes it a valuable candidate for enhancing the effectiveness of immunotherapies in treating a variety of tumors with elevated TGF-β levels.

Antitumor Activity of Asiaticoside Against Multiple Myeloma Drug-Resistant Cancer Cells is Mediated by Autophagy Induction, Activation of Effector Caspases, and Inhibition of Cell Migration, Invasion, and STAT-3 Signaling Pathway

Asiaticoside Antagonizes Proliferation and Chemotherapeutic Drug Resistance in Hepatocellular Carcinoma (HCC) Cells.

Anticancer activity in human multiple myeloma U266 cells: synergy between cryptotanshinone and arsenic trioxide.

Induction of cell cycle arrest and apoptosis by CPUC002 through stabilization of p53 and suppression of STAT3 signaling pathway in multiple myeloma

Matrine induces autophagic cell death by triggering ROS/AMPK/mTOR axis and apoptosis in multiple myeloma

Asiaticoside modulates human NK cell functional fate by mediating metabolic flexibility in the tumor microenvironment

MAPK Cascade Signaling is Involved in Α-Mmc Induced Growth Inhibition of Multiple Myeloma MM.1S Cells Via G2 Arrest and Mitochondrial-Pathway-Dependent Apoptosis in Vitro.

Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation

Aspirin Inhibits Proliferation and Induces Apoptosis of Multiple Myeloma Cells Through Regulation of Bcl‐2 and Bax and Suppression of VEGF

Resveratrol Induces AMPK and Mtor Signaling Inhibition-Mediated Autophagy and Apoptosis in Multiple Myeloma Cells.

Mesenchymal stem cells derived from multiple myeloma patients protect against chemotherapy through autophagy-dependent activation of NF-κB signaling

Dihydrocelastrol Inhibits Multiple Myeloma Cell Proliferation And Promotes Apoptosis Through Erk1/2 And Il-6/Stat3 Pathways In Vitro And In Vivo

Autophagy Inhibition Enhances Matrine Derivative MASM Induced Apoptosis in Cancer Cells Via a Mechanism Involving Reactive Oxygen Species-Mediated PI3K/Akt/mTOR and Erk/p38 Signaling

SR18292 Exerts Potent Antitumor Effects in Multiple Myeloma Via Inhibition of Oxidative Phosphorylation.

Synthesis of Sophocarpine Triflorohydrazone and Its Proliferation Inhibition and Apoptosis Induction Activity in Myeloma Cells Through Notch3‐p53 Signaling Activation

DCZ0801, a Novel Compound, Induces Cell Apoptosis and Cell Cycle Arrest Via MAPK Pathway in Multiple Myeloma.

Asiaticoside inhibits breast cancer progression and tumor angiogenesis via YAP1/VEGFA signal pathway

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

Resveratrol Sensitizes Carfilzomib-Induced Apoptosis Via Promoting Oxidative Stress in Multiple Myeloma Cells.

Shengma Biejia Decoction Inhibits Cell Growth in Multiple Myeloma by Inducing Autophagy-Mediated Apoptosis Through the ERK/mTOR Pathway

As4S4 Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2/STAT3 Signaling Pathway.